MedTrace Logo

The Pharmacokinetics (PK), Safety, Tolerability of SR750 (Formulation F1) in Healthy Volunteers

NCT06932536 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-12-31

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled phase I bridging study to evaluate the PK, safety and tolerability of SR750 (formulation F1) in Chinese healthy subjects.

Conditions

  • Healthy

Interventions

DRUG

SR750 tablet

Ascending single (30-100 mg) and multiple (30-60 mg twice daily \[b.i.d.\]) doses of SR750 orally

DRUG

Placebo

Ascending single and multiple doses of placebo orally

Sponsors & Collaborators

  • Shanghai SIMR Biotechnology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Qian Chen · Shanghai Clinical Research Center Phase I Clinical Research Unit (SCRC-PCRU)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-04-28
Primary Completion
2025-07-07
Completion
2025-07-07

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06932536 on ClinicalTrials.gov